Nichi-Iko Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the First Quarter of Fiscal Year Ending March 31, 2018; Provides Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2018
For the first half of fiscal year ending March 31, 2018, the company expects sales of JPY 99,000 million, operating profit of JPY 4,400 million, ordinary profit of JPY 4,200 million and net profit attributable to parent of JPY 2,700 million.
For the fiscal year ending March 31, 2018, the company expects sales of JPY 206,000 million, operating profit of JPY 9,000 million, ordinary profit of JPY 8,600 million, net profit attributable to parent of JPY 5,500 million, capital expense of JPY 10,568 million and depreciation of JPY 10,985 million.